Compare USNA & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | SLN |
|---|---|---|
| Founded | 1992 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.5M | 318.4M |
| IPO Year | 1996 | N/A |
| Metric | USNA | SLN |
|---|---|---|
| Price | $19.76 | $6.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $36.00 | ★ $39.67 |
| AVG Volume (30 Days) | 146.1K | ★ 310.4K |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $912,670,000.00 | $25,830,000.00 |
| Revenue This Year | $9.80 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.95 | ★ N/A |
| Revenue Growth | 5.88 | ★ 40.39 |
| 52 Week Low | $18.48 | $1.97 |
| 52 Week High | $38.32 | $8.08 |
| Indicator | USNA | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 49.73 |
| Support Level | $19.44 | $5.99 |
| Resistance Level | $20.03 | $6.59 |
| Average True Range (ATR) | 0.53 | 0.36 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 20.53 | 57.14 |
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.